Skin2Neuron
PrivateLast Round
Grant
Sep 22, 2025
Total Funding Raised
$2.9M
Company Overview
Skin2Neuron is a regenerative medicine company developing a first-in-class autologous neurorestorative cell therapy derived from human hair follicles to treat neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Skin2Neuron Comparables
Compare Skin2Neuron with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Regeneration Biomedical, Inc. | 80% | |
| Aspen Neuroscience | 76% | |
| UCB | 72% |
Skin2Neuron Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Sep 22, 2025 | ||||
| VC Round | Oct 1, 2024 | ||||
| Grant | May 1, 2024 |
Key People
Founding team and executive leadership
Skin2Neuron Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CUREator | Grant |
| Artesian | VC Round |
| SYNthesis BioVentures | VC Round |
| Karst Peak Rx | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 22, 2025
$1.55M grant round led by CUREator
- Aug 25, 2025
Grew 30% QoQ, from 10 to 13 employees.
Recent news
Latest coverage and updates
- is_developingOct 20, 2026
Skin2Neuron Pty develops an autologous cell therapy based on hair follicle-derived neuroprecursor cells, while Cell Therapies supports technology transfer and GMP clinical production for a 2027 first-in-human trial in Australia.
Skin2Neuron Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Skin2Neuron's valuation, stock price, and market status.
Is Skin2Neuron a public or private company?
Skin2Neuron is a private company.
What is the current stock price of Skin2Neuron?
Skin2Neuron is a private company, so its shares have no public market price. Caplight tracks Skin2Neuron's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Skin2Neuron worth (valuation)?
Valuation information for Skin2Neuron is not publicly available.
Can I buy Skin2Neuron stock?
Skin2Neuron shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Skin2Neuron's last funding round?
Skin2Neuron's most recent funding round was Grant on September 22, 2025.
Who are the main investors in Skin2Neuron?
Key investors in Skin2Neuron include SYNthesis BioVentures.
Will Skin2Neuron IPO soon?
No public IPO plans have been announced for Skin2Neuron.
How can I track Skin2Neuron secondary market activity?
Caplight tracks bids, offers, and trades in Skin2Neuron's shares on secondary markets.